Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Mechanism-based influenza neuraminidase inhibitors as antivirals to combat flu infections

Project description

New tech to inhibit influenza neuraminidase

Anti-influenza drugs, such as Oseltamivir and Zanamivir, target influenza neuraminidases. New compounds, N-acyl Oseltamivir aziridines (Aziflus), covalently inhibit these enzymes, blocking viral growth more permanently and selectively. They may be more effective than current treatments and useful for prevention and later disease stages. The ERC-funded AziFlu project aims to develop a technology to inhibit influenza neuraminidase and establish a start-up company to market it. The project will optimise compounds through synthesis and biochemical evaluations, design a route for large-scale production, and develop assays to assess target inhibition and viral response. To support the spin-out biotech company’s establishment, it will enhance its intellectual property position and analyse the anti-influenza drug market, facilitating the IP transfer to the new entity.

Objective

Influenza neuraminidases are the primary target for anti-influenza small molecule drugs and are retaining glycosidases that form a transient covalent intermediate during substrate hydrolysis. Oseltamivir (Tamiflu) and Zanamivir (Relenza), the two small-molecule anti-influenza drugs used primarily for early onset treatment of flu infections, inhibit influenza neuraminidases competitively (and thus reversibly). The AziFlu ERC PoC proposal is rooted in our finding that N-acyl Oseltamivir aziridines, or Aziflus, inhibit influenza neuraminidase covalently. They block viral outgrowth in an infected cell model. Our compounds are at least as potent as Oseltamivir. Rather than temporarily disabling influenza neuraminidases, our technology acts in an irreversible, permanent, manner. Our drug candidates are selective for influenza neuraminidases over human neuraminidases, and we propose they may be more effective than existing drugs and may also find use as prophylactics and to treat later disease stages. The AziFlu program will develop our mechanism-based influenza neuraminidase inhibition technology and take the first steps to create a start-up company for bringing the technology to market. To strengthen our scientific case (experimental development, A), we will (A-I) optimise our leads by the synthesis and biochemical evaluation of comprehensive sets of focused analogues; (A-II) design a synthetic route to prepare gram-scale quantities of selected leads; and (A-III) develop assays for in vitro and in vivo target inhibition efficacy, target engagement, and viral outgrowth studies. To prepare for the establishment of a spin-out biotech company (business development, B) to take our leads towards the clinic we will (B-IV) strengthen our intellectual property (IP) position; (B-V) analyse the anti-influenza drug market; and (B-VI) create a start-up biotech company to which the IP will be transferred.

Fields of science (EuroSciVoc)

This project has not yet been classified with EuroSciVoc.
Be the first one to suggest relevant scientific fields and help us improve our classification service

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2025-POC

See all projects funded under this call

Host institution

UNIVERSITEIT LEIDEN
Net EU contribution
€ 150 000,00
Address
RAPENBURG 70
2311 EZ Leiden
Netherlands
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Beneficiaries (1)